149 related articles for article (PubMed ID: 35997524)
1. Impact of intratumoural CD96 expression on clinical outcome and therapeutic benefit in gastric cancer.
Xu C; Fang H; Gu Y; Yu K; Wang J; Lin C; Zhang H; Li H; He H; Liu H; Li R
Cancer Sci; 2022 Dec; 113(12):4070-4081. PubMed ID: 35997524
[TBL] [Abstract][Full Text] [Related]
2. Impact of intratumoural CD73 expression on prognosis and therapeutic response in patients with gastric cancer.
He X; Gu Y; Cao Y; Hu B; Fang H; Fei Y; Lv K; Liu X; Wang J; Lin C; Liu H; Zhang H; Li H; Li R; He H; Xu J
Eur J Cancer; 2021 Nov; 157():114-123. PubMed ID: 34508993
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral IL-1R1 expression delineates a distinctive molecular subset with therapeutic resistance in patients with gastric cancer.
Zhang P; Gu Y; Fang H; Cao Y; Wang J; Liu H; Zhang H; Li H; He H; Li R; Lin C; Xu J
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110359
[TBL] [Abstract][Full Text] [Related]
4. Poor Clinical Outcomes and Immunoevasive Contexture in Intratumoral IL-10-Producing Macrophages Enriched Gastric Cancer Patients.
Zhang H; Li R; Cao Y; Gu Y; Lin C; Liu X; Lv K; He X; Fang H; Jin K; Fei Y; Chen Y; Wang J; Liu H; Li H; Zhang H; He H; Zhang W
Ann Surg; 2022 Apr; 275(4):e626-e635. PubMed ID: 32541216
[TBL] [Abstract][Full Text] [Related]
5. Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
Li W; Liu Z; Jin K; Shao F; Zeng H; Wang Y; Zhu Y; Xu L; Wang Z; Chang Y; Zhang W
BMC Cancer; 2023 Jul; 23(1):661. PubMed ID: 37452272
[TBL] [Abstract][Full Text] [Related]
6. Latency-associated Peptide Identifies Immunoevasive Subtype Gastric Cancer With Poor Prognosis and Inferior Chemotherapeutic Responsiveness.
Cao Y; He H; Li R; Liu X; Chen Y; Qi Y; Yu K; Wang J; Lin C; Liu H; Zhang H; Li H; Chen L; Zhang P; Shen Z; Huang H; Sun Y; Zhang W; Qin J; Xu J
Ann Surg; 2022 Jan; 275(1):e163-e173. PubMed ID: 32511132
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral Foxp3
Fei Y; Cao Y; Gu Y; Fang H; Chen Y; Wang J; Liu X; Lv K; He X; Lin C; Liu H; Li H; He H; Li R; Zhang H; Zhang W
Cancer Immunol Immunother; 2022 Jan; 71(1):1-11. PubMed ID: 33978826
[TBL] [Abstract][Full Text] [Related]
8. Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy.
Gu Y; Zhang P; Wang J; Lin C; Liu H; Li H; He H; Li R; Zhang H; Zhang W
Cancer Immunol Immunother; 2023 May; 72(5):1199-1208. PubMed ID: 36369379
[TBL] [Abstract][Full Text] [Related]
9. Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis.
Ye R; Zeng H; Liu Z; Jin K; Liu C; Yan S; Yu Y; You R; Zhang H; Chang Y; Wang Y; Liu L; Zhu Y; Xu J; Xu L; Wang Z
Cancer Immunol Immunother; 2022 Feb; 71(2):301-310. PubMed ID: 34152439
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome and molecular landscape of patients with ARID1A-loss gastric cancer.
Sun M; Gu Y; Fang H; Shao F; Lin C; Zhang H; Li H; He H; Li R; Wang J; Liu H; Xu J
Cancer Sci; 2024 Mar; 115(3):905-915. PubMed ID: 38148578
[TBL] [Abstract][Full Text] [Related]
11. Immune inactivation by APOBEC3B enrichment predicts response to chemotherapy and survival in gastric cancer.
Xia S; Gu Y; Zhang H; Fei Y; Cao Y; Fang H; Wang J; Lin C; Zhang H; Li H; He H; Xu J; Li R; Liu H; Zhang W
Oncoimmunology; 2021; 10(1):1975386. PubMed ID: 34552824
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral PD-1
Yu K; Gu Y; Zhang P; Fang H; Cao Y; Wang J; Lin C; Liu H; Zhang H; He H; Li R; Qin J; Li H; Xu J
Br J Cancer; 2022 Nov; 127(9):1709-1717. PubMed ID: 36002752
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive MFAP2
Wei R; Song J; Liu X; Huo S; Liu C; Liu X
Cell Oncol (Dordr); 2024 Feb; 47(1):55-68. PubMed ID: 37540308
[TBL] [Abstract][Full Text] [Related]
14. Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia.
Wang D; Wang N; Li X; Chen X; Shen B; Zhu D; Zhu L; Xu Y; Yu Y; Shu Y
Gastric Cancer; 2021 Jul; 24(4):823-834. PubMed ID: 33687617
[TBL] [Abstract][Full Text] [Related]
15. Tumor-infiltrating podoplanin
Liu X; Cao Y; Lv K; Gu Y; Jin K; He X; Fang H; Fei Y; Shi M; Lin C; Liu H; Li H; He H; Xu J; Li R; Zhang H
Oncoimmunology; 2020 Nov; 9(1):1845038. PubMed ID: 33235820
[TBL] [Abstract][Full Text] [Related]
16. Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients.
Jin K; Cao Y; Gu Y; Fang H; Fei Y; Wang J; Liu X; Lv K; He X; Lin C; Liu H; Li H; He H; Li R; Zhang H; Xu J
Oncoimmunology; 2021 Apr; 10(1):1915560. PubMed ID: 33996266
[TBL] [Abstract][Full Text] [Related]
17. Poor clinical outcomes of intratumoral dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin-positive macrophages associated with immune evasion in gastric cancer.
Liu X; Cao Y; Li R; Gu Y; Chen Y; Qi Y; Lv K; Wang J; Yu K; Lin C; Liu H; Zhang H; He H; Chen L; Zhang P; Shen Z; Qin J; Sun Y; Li H; Huang H; Zhang W; Xu J
Eur J Cancer; 2020 Mar; 128():27-37. PubMed ID: 32109848
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral IL17-producing cells infiltration correlate with antitumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer.
Wang JT; Li H; Zhang H; Chen YF; Cao YF; Li RC; Lin C; Wei YC; Xiang XN; Fang HJ; Zhang HY; Gu Y; Liu X; Zhou RJ; Liu H; He HY; Zhang WJ; Shen ZB; Qin J; Xu JJ
Ann Oncol; 2019 Feb; 30(2):266-273. PubMed ID: 30445581
[TBL] [Abstract][Full Text] [Related]
19. TIM3
Chen K; Gu Y; Cao Y; Fang H; Lv K; Liu X; He X; Wang J; Lin C; Liu H; Zhang H; He H; Xu J; Li H; Li R
Br J Cancer; 2022 Jan; 126(1):100-108. PubMed ID: 34725458
[TBL] [Abstract][Full Text] [Related]
20. Immune and Clinical Features of
Zhang Q; Zhong H; Fan Y; Liu Q; Song J; Yao S; Cao F
Front Bioeng Biotechnol; 2020; 8():592. PubMed ID: 32695752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
